| Literature DB >> 10936882 |
D L Sparks1, T A Martin, D R Gross, J C Hunsaker.
Abstract
Increased prevalence of Alzheimer's disease-like beta-amyloid deposits in the neuropil and within neurons occurs in the brains of non-demented individuals with heart disease. Heart disease is a prevalent finding in Alzheimer's disease, and may be a forerunner to the dementing disorder. In the cholesterol-fed rabbit model of human coronary heart disease there is production and accumulation of beta-amyloid in the brain. This accumulation of beta-amyloid can be reversed by removing cholesterol from the rabbits' diet. In culture cells, a cholesterol challenge has been shown to increase production of beta-amyloid, and dramatic reductions of cholesterol produced by HMG Co-A reductase inhibitors decrease production of beta-amyloid. Increased beta-amyloid production is also produced by dietary cholesterol in a number of transgenic mouse models of Alzheimer's disease. Administration of HMG Co-A reductase inhibitors may block beta-amyloid production caused by dietary cholesterol in rabbits. Clinical trials testing the benefit of HMG Co-A reductase inhibitors in the treatment of Alzheimer's disease are underway. Copyright 2000 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10936882 DOI: 10.1002/1097-0029(20000815)50:4<287::AID-JEMT7>3.0.CO;2-L
Source DB: PubMed Journal: Microsc Res Tech ISSN: 1059-910X Impact factor: 2.769